Polyester industry chain is faced with serious challenges by Covid-19
Affected by the epidemic, all industrial chains are facing different degrees of difficulties.A few days ago, interviews with a number of enterprises, polyester industry chain is going through the last few years the coldest "winter", difficult to return to work, logistics, inventory backlog, capital turnover inconvenience and other difficulties, are constantly "pressure" on enterprises.
In February, the overall inventory of PTA industry was overstocked as high as one million tons, and most enterprises were facing difficulties in production and operation.However, companies that use derivatives for risk management are relatively optimistic.Xu jien, deputy general manager of yisheng petrochemical PTA sales center, said that during the epidemic period, the enterprises using futures hedging, basically solved the problem of the sales end, but also effectively resolved the risk of high inventory." The company USES derivatives for risk management and effectively solves risks such as inventory accumulation, cost rise and basis fluctuation by selling hedging, hedging of processing fees and arbitrage.
2026-08-01
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
BASF Coatings Expands Polyester and Polyurethane Resin Capacity in Shanghai
-
Is Polyester a Plastic? A Definitive Explanation and Concepts
-
Arkema has announced plans to double its REAFREE polyester resin capacity in India
-
Pfizer's paxlovid reduces the risk of COVID-19 by 26%
-
The battle between Pfizer and Gilead over COVID-19 drugs will continue
-
1200 cases were newly prescribed by Junshi Biologic for mild to moderate disease
-
Cost Pressure has Increased Sharply, and Many Polyester Companies are 'Warming Together' to Cope with High Inventory
-
Rising Costs and Improving Demand, PTA Prices Continue to Soar
-
Twenty-five COVID-19 Vaccines In China Enter Stages Of Clinical Trials
-
Pfizer to Increase Production Capacity of COVID-19 Oral Drugs, Invest 120 Million US Dollars
Recommend Reading
-
Glyphosate Faces New UK Pressure as EU Trade Alignment Returns to the Debate
-
U.S. API Dependence Turns Pharmaceutical Ingredients Into a National Security Issue
-
FDA Dye Phase-Out Push Opens a Bigger Window for Natural Color Solutions
-
Pharma Tariff Risk Pushes Global Drugmakers to Rebuild U.S. Supply Chains
-
Global Chemical Giants Light the Fuse: A TDI/MDI Price Storm Sweeps Asia and Europe—Who’s Fueling This “Cost Carnival”?
-
Intensifying Long and Short Positions in Lithium Carbonate, Market Trends Downward
-
2026 Week 20 Market Observation: Formic Acid and Phosphoric Acid Strongly Surge, Melamine and Other Varieties Plunge Significantly
-
China's SBR Prices Rise Driven by Costs
-
Fundamentals Weakened, Polyester Staple Fiber Price Center of Gravity Shifts Lower
-
This Week's Activated Carbon Prices Remain Stable (5.18-5.22) in China